Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Multiple Myeloma 192Lymphoma 102Lymphoma, Non-Hodgkin 90Leukemia, Myeloid, Acute 89Precursor Cell Lymphoblastic Leukemia-Lymphoma 81Myelodysplastic Syndromes 81Hodgkin Disease 67Leukemia 66Neoplasms, Plasma Cell 65Lymphoma, Large B-Cell, Diffuse 59Leukemia, Lymphocytic, Chronic, B-Cell 58Lymphoma, Mantle-Cell 52Lymphoma, Follicular 49Burkitt Lymphoma 39Lymphoma, Large-Cell, Immunoblastic 35Lymphoma, B-Cell, Marginal Zone 34Myeloproliferative Disorders 30Recurrence 28Hematologic Neoplasms 28Neuroblastoma 25Leukemia, Myelogenous, Chronic, BCR-ABL Positive 25Leukemia, Myeloid, Accelerated Phase 24Graft vs Host Disease 23Leukemia, Myelomonocytic, Chronic 22Leukemia, Myeloid, Chronic-Phase 22Congenital Abnormalities 21Immunoglobulin Light-chain Amyloidosis 20Dendritic Cell Sarcoma, Interdigitating 19Primary Myelofibrosis 18Waldenstrom Macroglobulinemia 17

Interventions

venetoclax 1fludarabine 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Venentoclax × Melphalan × Clear all
NCT07396480 2026-03-17

Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

First Affiliated Hospital of Zhejiang University

Phase 3 Recruiting
186 enrolled
Other neoplasm

Venentoclax

Data powered by HemOnc (CC BY 4.0) Colophon âš¡